In search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)

Journal of Medicinal Chemistry

Volumn 48, Issue 6, 2005, Pages 1901-1909

  Janssen, Paul A J ^a   Lewi, Paul J ^a   Arnold, Eddy ^b   Daeyaert, Frits ^a   De Jonge, Marc ^a   Heeres, Jan ^a   Koymans, Luc ^a   Vinkers, Maarten ^a   Guillemont, Jérôme ^c   Pasquier, Elisabeth ^d   Kukla, Mike ^d   Ludovici, Don ^d   Andries, Koen ^e   De Béthune, Marie Pierre ^e   Pauwels, Rudi ^e   Das, Kalyan ^b   Clark Jr , Art D ^b   Frenkel, Yulia Volovik ^b   Hughes, Stephen H ^f   Medaer, Bart ^g   De Knaep, Fons ^h   Bohets, Hilde ^g   De Clerck, Fred ^g   Lampo, Ann ^g   Williams, Peter ⁱ   Stoffels, Paul ^e   more..

^a Center for Molecular Design   (Belgium)

^b RUTGERS UNIVERSITY   (United States)

^c Medicinal Chemistry   (France)

^d Drug Discovery   (United States)

^e Virco BVBA   (Belgium)

^f NATIONAL CANCER INSTITUTE   (United States)

^g Drug Evaluation   (Belgium)

^h Janssen Pharmaceutica   (Belgium)

ⁱ NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAPIVIRINE; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GOITER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER WEIGHT; MALE; MOLECULAR MODEL; MUTANT; NONHUMAN; PLASMA PROTEIN BINDING; RAT; VIROLOGY; WILD TYPE;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOME, VIRAL; HIV; HIV INFECTIONS; HUMANS; INTERDISCIPLINARY COMMUNICATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NITRILES; PYRIMIDINES;

EID: 20144372481     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040840e     Document Type: Article

References (60)

1. Coffin, J. M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
2. WHO/UNAIDS. Global summary of the HIV/AIDS epidemic. WHO report (December 2002). http://www.who.int/hiv/pub/epidemiology/epi2002/en/
3. Coffin, J. M.; Hughes, S. H.; Varmus, H. E. Retroviruses; Cold Spring Harbor Laboratory Press: Plainview, NY, 1997.
4. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St Clair, M. H.; Lehrman, S. N.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3′-Azido- 3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
5. Mitsuya, H.; Broder, S. Strategies for antiviral therapy in AIDS. Nature 1987, 325, 773-778.
6. Larder, B. A.; Kemp, S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246, 1155-1158.
7. Richman, D. D. HIV drug resistance. AIDS Res. Human Retroviruses 1992, 8, 1065-1071.
8. Telesnitsky, A.; Goff, S. P. Reverse transcriptase and the generation of retroviral DNA. In Retroviruses; Coffin, J. M., Hughes, S. H., Varmus, H. E., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY., 1997; pp 121-160.
9. Stephenson, J. The art of 'HAART': Researchers probe the potential and limits of aggressive HIV treatments. JAMA 1997, 277, 614-616.
10. Gazzard, B. The picture of future therapy. Int. J. Clin. Pract. Suppl. 1999, 103, 45-48.
11. Lalezari, J. P.; Henry, K.; O'Hearn, M.; Montaner, J. S.; Piliero, P. J.; Trottier, B.; Walmsley, S.; Cohen, C.; Kuritzkes, D. R.; Eron, J. J., Jr.; Chung, J.; DeMasi, R.; Donatacci, L.; Drobnes, C.; Delehanty, J.; Salgo, M. TORO 1 Study Group. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. N. Engl. J. Med. 2003, 348, 2175-2185.
12. De Clercq, E. New anti-HIV agents and targets. Med. Res. Rev. 2002, 22, 531-565
13. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Das, K.; Arnold, E.; Janssen, P. A. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
14. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H. J.; Raeymaeckers, A.; Van Gelder, J.; Woestenborghs, R.; Heykants, J.; Schellekens, K.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
15. Pauwels, R.; Andries, K.; Debyser, Z.; Daele, P. V.; Schols, D.; Stoffels, P.; Vreese, K. D.; Woestenborghs, R.; Vandamme, A.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
16. Ludovici, D. W.; Kukla, M. J.; Grous, P. G.; Krishnan, S.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; De Clercq, E.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates. Part 1: From alpha- Anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU). Bioorg. Med. Chem. Lett. 2001, 11, 2225-2228.
17. Ludovici, D. W.; Kavash, R. W.; Kukla, M. J.; Ho, C. Y.; Ye, H.; De Corte, B. L.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Moereels, H. E.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Lewi, P. J.; Das, K.; Arnold, E.; Janssen, P. A. J. Evolution of anti-HIV drug candidates Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2229-2234.
18. Gruzdev, B.; Horban, A.; Boron-Kaczmarska, A.; Gille, D.; van 't Klooster, G.; Pauwels, R. TMC120, a New Non- Nucleoside Reverse Transcriptase Inhibitor, Is a Potent Antiretroviral in Treatment Naive, HIV-1 Infected Subjects. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8, 2001. Abstract 13.
19. Sankatsing, S.; Weverling, G.; van 't Klooster, G.; Prins, J.; Lange, J. TMC125 Monotherapy for 1 Week Results in a Similar Initial Rate of Decline of HIV-1 RNA as Therapy with a 5-Drug Regimen. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002. Abstract 5.
20. Gazzard, B.; Pozniak, A.; Arasteh, K.; Staszwski, S.; Rozenbaum, W.; Yeni, P.; van't Klooster, G.; De Dier, K.; Peeters, M.; de Béthune, M.-P.; Graham, N.; Pauwels, R. TMC125, A Next-Generation NNRTI, Demonstrates High Potency After 7 Days Therapy in Treatment-Experienced HIV-1-Infected Individuals with Phenotypic NNRTI Resistance. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002. Abstract 4.
21. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
22. Jacobo-Molina, A.; Ding, J.; Nanni, R. G.; Clark, A. D., Jr.; Lu, X.; Tantillo, C.; Williams, R. L.; Kamer, G.; Ferris, A. L.; Clark, P.; Hizi, A.; Hughes, S. H.; Arnold, E. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6320-6324.
23. Hsiou, Y.; Das, K.; Ding, J.; Tantillo, C.; Boyer, P. L.; Hughes, S. H.; Arnold, E. The role of nucleic acid in the resistance of HIV-1 reverse transcriptase to nucleoside and nonnucleoside inhibitors. Med. Biol. Environ. 1995, 23, 209-215.
24. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
25. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 407-415.
26. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D., Jr.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H., Jr.; Kroeger Smith, M. B.; Koepke, M.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non- nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
27. Ren, J.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure 1995, 3, 915-926.
28. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D., Jr.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A. J.; Boyer, P. L.; Clark, P.; Smith, R. H., Jr.; Smith, M. B. K.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 1986, 264, 1085-1100.
29. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
30. Hsiou, Y.; Das, K.; Ding, J.; Clark, A. D., Jr.; Kleim, J. P.; Rosner, M.; Winkler, I.; Riess, G.; Hughes, S. H.; Arnold, E. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the nonnucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 1998, 284, 313-323.
31. Ren, J.; Esnouf, R. M.; Hopkins, A. L.; Stuart, D. I.; Stammers, D. K. Crystallographic analysis of the binding modes of thiazoloisoindolinone nonnucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. J. Med. Chem. 1999, 42, 3845-3851.
32. Sarafianos, S. G.; Das, K.; Clark, A. D., Jr.; Ding, J.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10027-10032.
33. Ren, J.; Milton, J.; Weaver, K. L.; Short, S. A.; Stuart, D. I.; Stammers, D. K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Des. 2000, 8, 1089-1094.
34. Hsiou, Y.; Ding, J.; Das, K.; Clark, A. D., Jr.; Boyer, P. L.; Lewi, P.; Janssen, P. A.; Kleim, J. P.; Rosner, M.; Hughes, S. H.; Arnold, E. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. J. Mol. Biol. 2001, 309, 437-445.
35. Ren, J.; Nichols, C.; Bird, L.; Chamberlain, P.; Weaver, K.; Short, S.; Stuart, D. I.; Stammers, D. K. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation nonnucleoside inhibitors. J. Mol. Biol. 2001, 372, 795-809.
36. Lindberg, J.; Sigurdsson, S.; Lowgren, S.; Andersson, H. O.; Sahlberg, C.; Noreen, R.; Fridborg, K.; Zhang, H.; Unge, T. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 2002, 269, 1670-1677.
37. Das, K.; Clark, A. D., Jr.; Lewi, P. J.; Heeres, J.; De Jonge, M. R.; Koymans, L. M.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels R.; De Béthune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A.; Arnold, E. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 2004, 47, 2550-2560.
38. Lewi, P. J.; de Jonge, M.; Daeyaert, F.; Koymans, L.; Vinkers, M.; Heeres, J.; Janssen, P. A. J.; Arnold, E.; Das, K.; Clark, A. D., Jr.; Hughes, S. H.; Boyer, P. L.; de Béthune, M.-P.; Pauwels, R.; Andries, K.; Kukla, M.; Ludovici, D.; De Corte, B.; Kavash, R.; Ho, C. On the dectection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data. J. Comput. Aid. Des. 2003, 17, 129-134.
39. Halgren, T. A. Merck molecular force field: I. Basis, form, scope, parametrization and performance of MMFF94. J. Comput. Chem. 1998, 17, 490-519.
40. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clercq, E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
41. Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Béthune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M.; de Jonge, M. R.; Van Aken, K. J.; Daeyaert, F. F.; Das, K.; Arnold E.; Janssen P. A. J. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg. Med. Chem. Lett. 2001, 11, 2235-2239.
42. Lewi, P.; Arnold, E.; Andries, K.; Bohets, H.; Borghys H.; Clark, A. D., Jr.; Daeyaert F.; Das, K.; de Béthune M.-P.; de Jonge, M.; Heeres, J.; Koymans, L.; Leempoels, J.; Peeters, J.; Timmerman, Ph.; Van den Broeck, W.; Vanhoutte, F.; van't Klooster, G.; Vinkers, M.; Volovik, Y.; Janssen, P. A. J. Correlations between Factors Determining the pharmacokinetics and Antiviral Activity of HIV-1 nonnucleoside reverse transcriptase inhibitors of the Diaryltriazine and Diarylpyrimidine classes of compounds. Drugs R & D 2004, 5, 245-257.
43. Volovik Frenkel, Y.; Clark, A. D., Jr.; Das, K.; Wang, Y.; Lewi, P. J.; Janssen, P. A. J.; Arnold, E. Concentration and pH dependence of aggregation of hydrophobic drug molecules and relevance to oral bioavailability. J. Med. Chem., in press.
44. Seidler, J.; McGovern, S. L.; Doman, T. N.; Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 2003, 46, 4477-4486.
45. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition. J. Med. Chem. 2003, 46, 4265-4272.
46. Washington, C. Particle size analysis in pharmaceutical and other industries; Ellis Norwood: New York, 1992; pp 135-167.
47. Bohets, H.; Annaert, P.; Mannens, G.; van Beijsterveldt, L.; Anciaux, K.; Verboven, P.; Meuldermans, W.; Lavrijsen K. Strategies for drug screening in drug discovery and development. Curr. Top. Med. Chem. 2001, 1, 367-383.
48. Yeh, P.-Y.; Ellens, H.; Smith, P. L. Physiological considerations in the design of particulate dosage forms for oral vaccine delivery. Adv. Drug Deliv. Rev. 1998, 34, 123-133.
49. Popper, H. Distribution of vitamin A in tissues as visualized by fluorescence microscopy. Physiol. Rev. 1944, 24, 205-224.
50. Charman, W. N.; Stella, V. J. Lymphatic transport of drugs; CRC Press: Boca Raton, FL, 1992.
51. Dorland, W. A. Dorland's illustrated medical dictionary; W. B. Saunders: Philadelphia, PA, 1981; p 761.
52. Andries, K.; Azijn, H.; Thielemans, T.; Ludovici, D.; Kukla, M.; Heeres, J.; Janssen, P.(+); De Corte, B.; Pauwels, R.; de Béthune, M.-P. TMC125, a novel next generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant HIV-1. AACN Clin. Issues 2004, in press
53. Clive, D.; Caspary, W.; Kirby, P.; Krehl. R.; Moore, M.; Mayo, J.; Oberly, T. J. Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutation Res. 1987, 189, 143-156.
54. EEC test method B. 12. Micronucleus test. Annex to the Commission Directive 92/69 EEC, adapting Council Directive 67/548/EEC, July 31, 1992
55. Boulton, A. A.; Baker, G. B.; Hrdina, P. D. Receptor Binding; Humana Press: Totowa, NJ, 1986.
56. Smet, F.; D'Aubioul, J.; van Gerven, W.; Xhonneux, R.; Reneman, RS. A chronically implantable catheter-tip micromanometer (JSI 0400) that can be calibrated after implantation. Cardiovasc. Res. 1979, 13, 601-605.
57. Wolford, S. T.; Schroer, R. A.; Gohs, F. X.; Gallo, P. P.; Brodeck, M.; Falk, H. B.; Ruhren, R. Reference range database for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Health 1986, 18, 161-88.
58. Lewi, P. J.; Marsboom, R. P. Toxicology Reference Data - Wistar Rat; Elsevier Biomedical Press: Amsterdam, 1981; pp 265-343.
59. International Conference on Harmonisation: Guidelines on the Assessment of Systemic Exposure in Toxicity Studies. FDA, Fed. Regist. 1995, 60, 11264-11268.
60. Guillemont, J.; Pasquier, E.; Palandjian, P.; Vernier, D.; Gaurrand, S.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Daeyaert, F. F. D.; Vinkers, M. H.; Arnold, E.; Das, K.; Pauwels, R.; Andries, K.; de Béthune, M.-P.; Bettens, E.; Hertogs, K.; Wigerinck, P.; Timmerman, P.; Janssen, P. A. J. Synthesis of novel diarylpyrimidine (DAPY) analogues and their antiviral activity against HIV-1. J. Med. Chem., in press.